These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23836971)

  • 121. Preparation, characterization, and in vivo evaluation of tanshinone IIA solid dispersions with silica nanoparticles.
    Jiang YR; Zhang ZH; Liu QY; Hu SY; Chen XY; Jia XB
    Int J Nanomedicine; 2013; 8():2285-93. PubMed ID: 23836971
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Improvement in oral bioavailability and dissolution of tanshinone IIA by preparation of solid dispersions with porous silica.
    Yan HM; Sun E; Cui L; Jia XB; Jin X
    J Pharm Pharmacol; 2015 Sep; 67(9):1207-14. PubMed ID: 25944009
    [TBL] [Abstract][Full Text] [Related]  

  • 123. An attempt to stabilize tanshinone IIA solid dispersion by the use of ternary systems with nano-CaCO3 and poloxamer 188.
    Yan HM; Zhang ZH; Jiang YR; Ding DM; Sun E; Jia XB
    Pharmacogn Mag; 2014 Apr; 10(Suppl 2):S311-7. PubMed ID: 24991109
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Enhanced dissolution and stability of Tanshinone IIA base by solid dispersion system with nano-hydroxyapatite.
    Jiang YR; Zhang ZH; Huang SY; Lu Y; Ma TT; Jia XB
    Pharmacogn Mag; 2014 Jul; 10(39):332-7. PubMed ID: 25210322
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Enhanced dissolution and oral bioavailability of tanshinone IIA base by solid dispersion system with low-molecular-weight chitosan.
    Liu QY; Zhang ZH; Jin X; Jiang YR; Jia XB
    J Pharm Pharmacol; 2013 Jun; 65(6):839-46. PubMed ID: 23647677
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Enhancement of solubility and dissolution rate of cryptotanshinone, tanshinone I and tanshinone IIA extracted from Salvia miltiorrhiza.
    Yu H; Subedi RK; Nepal PR; Kim YG; Choi HK
    Arch Pharm Res; 2012 Aug; 35(8):1457-64. PubMed ID: 22941489
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation.
    Hu K; Cao S; Hu F; Feng J
    Int J Nanomedicine; 2012; 7():3537-45. PubMed ID: 22848177
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Use of the co-grinding method to enhance the dissolution behavior of a poorly water-soluble drug: generation of solvent-free drug-polymer solid dispersions.
    Yang C; Xu X; Wang J; An Z
    Chem Pharm Bull (Tokyo); 2012; 60(7):837-45. PubMed ID: 22790815
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Solubility enhancement of desloratadine by solid dispersion in poloxamers.
    Kolašinac N; Kachrimanis K; Homšek I; Grujić B; Ðurić Z; Ibrić S
    Int J Pharm; 2012 Oct; 436(1-2):161-70. PubMed ID: 22772487
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil.
    Shi F; Zhao JH; Liu Y; Wang Z; Zhang YT; Feng NP
    Int J Nanomedicine; 2012; 7():2033-43. PubMed ID: 22619540
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles.
    Galagudza M; Korolev D; Postnov V; Naumisheva E; Grigorova Y; Uskov I; Shlyakhto E
    Int J Nanomedicine; 2012; 7():1671-8. PubMed ID: 22619519
    [TBL] [Abstract][Full Text] [Related]  

  • 132. The effect of functionalization of mesoporous silica nanoparticles on the interaction and stability of confined enzyme.
    Falahati M; Saboury AA; Ma'mani L; Shafiee A; Rafieepour HA
    Int J Biol Macromol; 2012 May; 50(4):1048-54. PubMed ID: 22421216
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Promising plasmid DNA vector based on APTES-modified silica nanoparticles.
    Cheang TY; Tang B; Xu AW; Chang GQ; Hu ZJ; He WL; Xing ZH; Xu JB; Wang M; Wang SM
    Int J Nanomedicine; 2012; 7():1061-7. PubMed ID: 22403488
    [TBL] [Abstract][Full Text] [Related]  

  • 134. In vitro release and in vitro-in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles.
    Cao X; Deng WW; Fu M; Wang L; Tong SS; Wei YW; Xu Y; Su WY; Xu XM; Yu JN
    Int J Nanomedicine; 2012; 7():753-62. PubMed ID: 22393284
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Physicochemical investigations and stability studies of amorphous gliclazide.
    Jondhale S; Bhise S; Pore Y
    AAPS PharmSciTech; 2012 Jun; 13(2):448-59. PubMed ID: 22382730
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery.
    Tang F; Li L; Chen D
    Adv Mater; 2012 Mar; 24(12):1504-34. PubMed ID: 22378538
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis.
    Corbalan JJ; Medina C; Jacoby A; Malinski T; Radomski MW
    Int J Nanomedicine; 2012; 7():631-9. PubMed ID: 22334785
    [TBL] [Abstract][Full Text] [Related]  

  • 138.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 139.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 140.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.